Veterinary medicinal products: Initial Appraisal of a European Commission Impact Assessment

29-04-2015

This note seeks to provide an initial analysis of the strengths and weaknesses of the European Commission's Impact Assessment (IA) accompanying the proposal for a Directive of on veterinary medicinal products. The proposal on veterinary medicines, together with the parallel proposal on medicated feed, is part of an overarching goal of the Commission to address the problem of rising threats from antimicrobial resistance in the EU. This note, prepared by the Ex-Ante Impact Assessment Unit for the Committee on Environment, Public Health and Food Safety (ENVI) of the European Parliament, analyses whether the principal criteria laid down in the Commission’s own Impact Assessment Guidelines, as well as additional factors identified by the Parliament in its Impact Assessment Handbook, appear to be met by the IA.

This note seeks to provide an initial analysis of the strengths and weaknesses of the European Commission's Impact Assessment (IA) accompanying the proposal for a Directive of on veterinary medicinal products. The proposal on veterinary medicines, together with the parallel proposal on medicated feed, is part of an overarching goal of the Commission to address the problem of rising threats from antimicrobial resistance in the EU. This note, prepared by the Ex-Ante Impact Assessment Unit for the Committee on Environment, Public Health and Food Safety (ENVI) of the European Parliament, analyses whether the principal criteria laid down in the Commission’s own Impact Assessment Guidelines, as well as additional factors identified by the Parliament in its Impact Assessment Handbook, appear to be met by the IA.